Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer.

Christos Fountzilas David L BajorSarbajit MukherjeeJoel SaltzmanAgnieszka K WitkiewiczOrla MaguireHans MindermanRam NambiarHanna R Rosenheck Erik S Knudsen Jason B Muhitch Scott I AbramsChong WangAlan D HutsonKristopher AttwoodKaren A HicksJennifer A JurcevicPawel KalinskiRenuka IyerPatrick M Boland

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

The combination of cetuximab and pembrolizumab is inactive in patients with RASwt mCRC, despite its partial local immunologic efficacy. Further development of immuno-oncology combinations with enhanced efficacy and/or targeting additional or alternative immune checkpoints merits investigation.

Keyphrases

wild type
advanced non small cell lung cancer
palliative care
cancer therapy
radiation therapy
drug delivery